Edgewise Therapeutics, Inc. EWTX

US Pharmaceuticals

$45.66 ▼ -6.32% ($-3.08)

Open $47.76

Prev Close $48.74

Day Range $44.79 – $47.80

52W Range $16.70 – $48.51

Market Cap $4.89B

Beta 0.39

EPS (TTM) $-1.85

📋 Company Profile

Industry	Pharmaceuticals
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2021-03-26
Shares Out.	108,600,000
Website	edgewisetx.com/ ↗
Phone	13026365401
Employees	133
Revenue	$0
Gross Profit	$0
Net Income	$1.17B
Free Cash Flow	-$202.3M
Total Assets	$1.78B
Total Liabilities	$147.4M
Equity	$1.63B

About Edgewise Therapeutics, Inc.

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.

Edgewise Therapeutics, Inc. is a publicly traded company under the ticker symbol EWTX on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.